Exclusive Summary

• Needle-free and ready-to-use nasal powder formulation revolutionizes severe hypoglycemia rescue, offering game-changing clinical replacement value.
• Temperature-stable portability: Can be carried in hot or cold conditions and stored at up to 86°F (30°C).
• For any weight, ages 1 year and above: Single, fixed, 3 mg dose.
• Extremely high technical barriers for drug-device combinations result in scarce generic competition, avoiding red-ocean price wars.
• Backed by top-tier regulatory approvals (US-FDA, EU-EMA, Japan), guaranteeing impeccable quality and enabling rapid commercialization globally.
• Highly endorsed by ADA guidelines for a massive target population of insulin-treated patients among the 537 million diabetics worldwide.
• Substantial cost advantages over the originator (Baqsimi) empower local distributors to win reimbursements and facilitate widespread prophylactic stocking.